John P Zajicek

Summary

Affiliation: Derriford Hospital
Country: UK

Publications

  1. ncbi Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study
    C B Carroll
    Department of Neurology, Derriford Hospital, Plymouth, UK
    Neurology 63:1245-50. 2004
  2. ncbi Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
    J P Zajicek
    Department of Mathematics and Statistics, University of Plymouth, Room N16, ITTC Building, Tamar Science Park, Plymouth, Devon PL6 8BX, UK
    J Neurol Neurosurg Psychiatry 76:1664-9. 2005
  3. ncbi Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis
    C L Hirst
    Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK
    J Neurol 255:231-8. 2008
  4. ncbi Multiple sclerosis
    John Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK Electronic address
    Handb Clin Neurol 110:461-70. 2013
  5. ncbi Role of cannabinoids in multiple sclerosis
    John P Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK
    CNS Drugs 25:187-201. 2011
  6. ncbi Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort
    John P Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, University of Plymouth, UK
    BMC Neurol 10:88. 2010
  7. ncbi Diagnosis and disease modifying treatments in multiple sclerosis
    J Zajicek
    Clinical Neurology Research, Room N16, ITTC building 1, Tamar Science Park, 1 Davy Road, Plymouth PL6 8BX, UK
    Postgrad Med J 81:556-61. 2005
  8. ncbi Neurosarcoidosis
    J P Zajicek
    Department of Neurology, Derriford Hospital, Plymouth, UK
    Curr Opin Neurol 13:323-5. 2000
  9. ncbi Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
    John Zajicek
    Peninsula Medical School, Plymouth, UK
    Lancet 362:1517-26. 2003
  10. ncbi Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease
    Javier Escudero
    Signal Processing and Multimedia Communications Research Group, School of Computing and Mathematics, Plymouth University, Plymouth, PL4 8AA, UK
    IEEE Trans Biomed Eng 60:164-8. 2013

Collaborators

Detail Information

Publications15

  1. ncbi Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study
    C B Carroll
    Department of Neurology, Derriford Hospital, Plymouth, UK
    Neurology 63:1245-50. 2004
    ..The authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in PD...
  2. ncbi Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
    J P Zajicek
    Department of Mathematics and Statistics, University of Plymouth, Room N16, ITTC Building, Tamar Science Park, Plymouth, Devon PL6 8BX, UK
    J Neurol Neurosurg Psychiatry 76:1664-9. 2005
    ..To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study...
  3. ncbi Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis
    C L Hirst
    Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK
    J Neurol 255:231-8. 2008
    ..Whilst side effects were common these were normally self limiting or easily managed, suggesting Campath 1-H may be of use in the treatment of very active relapsing remitting multiple sclerosis...
  4. ncbi Multiple sclerosis
    John Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK Electronic address
    Handb Clin Neurol 110:461-70. 2013
    ..The goals of preventing progress from early MS to secondary progression, and making any impact on progressive disease, remain elusive...
  5. ncbi Role of cannabinoids in multiple sclerosis
    John P Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK
    CNS Drugs 25:187-201. 2011
    ..Trials are currently under way to test whether cannabinoids may have a longer term role in reducing disability and progression in MS, in addition to symptom amelioration, where indications are being established...
  6. ncbi Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort
    John P Zajicek
    Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, University of Plymouth, UK
    BMC Neurol 10:88. 2010
    ....
  7. ncbi Diagnosis and disease modifying treatments in multiple sclerosis
    J Zajicek
    Clinical Neurology Research, Room N16, ITTC building 1, Tamar Science Park, 1 Davy Road, Plymouth PL6 8BX, UK
    Postgrad Med J 81:556-61. 2005
    ..The success and failure of agents that should be effective on theoretical grounds, together with advances in neuropathology, have led to fundamental questions regarding our basic understanding of disease pathogenesis being re-addressed...
  8. ncbi Neurosarcoidosis
    J P Zajicek
    Department of Neurology, Derriford Hospital, Plymouth, UK
    Curr Opin Neurol 13:323-5. 2000
    ....
  9. ncbi Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
    John Zajicek
    Peninsula Medical School, Plymouth, UK
    Lancet 362:1517-26. 2003
    ..Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis...
  10. ncbi Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease
    Javier Escudero
    Signal Processing and Multimedia Communications Research Group, School of Computing and Mathematics, Plymouth University, Plymouth, PL4 8AA, UK
    IEEE Trans Biomed Eng 60:164-8. 2013
    ..Thus, it may contribute to a personalized and effective detection of AD, and may prove useful in clinical settings...
  11. ncbi Therapeutic potential of cannabis in pain medicine
    R D Hosking
    Neurology Research Group, Peninsula Medical School, Plymouth, UK
    Br J Anaesth 101:59-68. 2008
    ..This review discusses the basic science and clinical aspects of CB pharmacology with a focus on pain medicine...
  12. ncbi The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease
    James Shearer
    Health Economics Group, Peninsula College of Medicine and Dentistry, University of Exeter, Veysey Building, Salmon Pool Lane, Exeter, EX2 4SG, UK
    J Neurol 259:462-8. 2012
    ....
  13. ncbi Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)
    J C Hobart
    Department of Clinical Neuroscience, Peninsula Medical School, Plymouth, Devon, UK
    Brain 129:224-34. 2006
    ..It has the potential to advance outcomes measurement in clinical trials and clinical practice, and provides a new perspective in the clinical evaluation of spasticity...
  14. ncbi The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria
    C M Fox
    Department of Neurology, Derriford Hospital, Plymouth, UK
    J Neurol Neurosurg Psychiatry 75:56-60. 2004
    ..This study reports one of the highest prevalences in the south of the UK, adding support for a north-south divide being a step effect rather than a latitudinal gradient...
  15. ncbi The 'harlequin' sign in association with multiple sclerosis
    C B Carroll
    J Neurol 251:1145-6. 2004